Navigation Links
GenVec Reports Fourth Quarter and 2010 Year-End Financial Results
Date:3/10/2011

ue to increased revenue of $7.5 million generated by our hearing loss and balance disorders  program.  We entered into a research collaboration and license agreement with Novartis in January 2010, which accounted for $3.4 million of revenue in 2010, and a development agreement related to the supply of clinical trial material related to activities under the collaboration agreement in August 2010, which accounted for $4.4 million in revenue in 2010.  The two Novartis agreements resulted in increased revenue in 2010 as compared to 2009 when the only work performed for our hearing loss and balance disorders program was performed under a grant from the University of Kansas. Partially offsetting the increased revenue associated with our hearing loss and balance disorders program is decreased revenue of $3.0 million and $2.2 million associated with our HIV and FMD programs, respectively, as compared to the prior years due to reduced work scope under each program.

Operating expenses for 2010 decreased 9% to $29.1 million from $31.9 million in 2009.  Research and development expenses decreased 15% to $20.9 million in 2010 from $24.7 million in 2009. The decrease is primarily due to lower costs related to the development of TNFerade including personnel, manufacturing costs, patient costs, and professional service costs related to our TNFerade pancreatic clinical trial, due to the termination of the clinical trial in the first quarter of 2010.  

General and administrative expenses increased 14% to $8.2 million in 2010 from $7.2 million in 2009. General and administrative expenses were higher in 2010 primarily due to higher professional service costs and facility costs, partially offset by lower depreciation costs.

Fourth Quarter 2010 ResultsFor the fourth quarter ended December 31, 2010, GenVec reported a net loss of $1.0 million, or $0.01 per share, compared with a net loss of $4.3 million, or $0.04 per share, for the comparab
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. GenVec Forms Collaboration With World-Leading Animal Health Company
2. GenVec Reports Third Quarter 2010 Financial Results
3. GenVec Receives Second-Year Funding From SAIC for HIV and Influenza Vaccine Development
4. GenVec Receives National Cancer Institute Grant to Expand Cancer Program
5. GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
6. Transgenomic Reports Fourth Quarter Financial Results
7. Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
8. Six-Month Prospective Multi-Center Study Reports Efficacy Rates for AMS Elevate Anterior and Apical Prolapse Repair System
9. Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group
10. Cardiogenesis Reports Fourth Quarter and Full Year 2010 Results
11. Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty ... disease and overall health is pleased to provide you with ... outlook for 2015 from the CEO, Mr. Eugene Bortoluzzi ... like to take this opportunity to share with you the ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015  Profil Institute ... focused on diabetes and obesity, announced today a new ... Drug Development,  published by Springer, a leading global scientific ... extensively analyze and illustrate techniques for use in early ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/x3hp3g/microbiology ) ... Testing/Clinical Microbiology Market by Product, Clinical Application & ... report to their offering. Clinical microbiology ... the detection of infectious diseases. The respiratory diseases ...
Breaking Medicine Technology:Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 3
... The Pharmaceutical,Research and Manufacturers of America (PhRMA) ... pipeline for major diseases affecting African,Americans to Mississippi ... pharmaceutical research companies are now testing 691 new,medicines ... or diseases that are among the top 10 ...
... 49th annual meeting recombinant factor, VIIa-albumin fusion protein ... treatment option for hemophilia patients with ... the,results of a pre-clinical study that show for the first ... human albumin, prolonging the,half- life of this therapeutic protein while ...
Cached Medicine Technology:New Report Offers Hope for Closing Health Gap for African Americans, With Nearly 700 Medicines in Pipeline 2New Report Offers Hope for Closing Health Gap for African Americans, With Nearly 700 Medicines in Pipeline 3CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity 2CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity 3
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader who consistently delivers ... to have it lead the wedding dress industry into the ... dresses for the global market. , “The CEO of VogueQueen ... focuses on continuing the goal of operational excellence and giving ...
(Date:1/22/2015)... is a famous wedding dress company offering many trendy designs. ... Facebook, Twitter, and Pinterest. The fans will have an opportunity ... every week. , Moreover, the company has extended its 2015 ... homepage for more information. , Angelweddingdress is a ...
(Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and David ... Show to bestow a Juvent Sports Achievement award upon ... McKitrick. The award commemorated and congratulated McKitrick for her ... won her first amateur tournament in 1979 and most ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo and ... federal multidistrict litigation underway in U.S. District Court, District ... Order dated January 20th, the Court has remanded a ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
... , , , ... Living, Inc. (OTC Bulletin Board: TCSR), which develops, manages and owns ... agreement with Deutsche Bank Berkshire Mortgage, Inc. for the development of ... Trinity Heights , an 82-unit, $10 ...
... , , WILTON, Conn., July ... BlogHer Conference 2009 held Friday, July 24 and Saturday, July 25 ... about the importance of incidental sun exposure and give them a ... Aging Simulator. This year marked Eucerin,s first appearance at the ...
... , ANN ARBOR, Mich., July 28 ... the vendor for the Treatment Cost Calculator, an application that ... healthcare services. The Treatment Cost Calculator also shows consumers how ... , Clear Choice is headquartered in Bend, Oregon, ...
... , , , ... July 28 Uptown Mt. Lebanon is the place to be Saturday, August ... ULTRAparty , Mt. Lebanon,s premiere summer street party event, from ... provides an opportunity for the young (and young-at-heart!) to literally party ...
... , , , ... The State of Louisiana and Together Rx Access announced today ... help thousands of eligible uninsured Louisianans access immediate and meaningful savings ... , , The collaboration will use existing ...
... ISLANDIA, N.Y., July 28 CA, Inc. (Nasdaq: ... integrated infrastructure and performance management solution to ... The CA solution will help Seattle Children,s achieve the benefits of ... and automated fault isolation and root cause analysis for the infrastructure ...
Cached Medicine News:Health News:TrinityCare Senior Living Announces Funding Agreement for Fifth Senior Living Facility 2Health News:TrinityCare Senior Living Announces Funding Agreement for Fifth Senior Living Facility 3Health News:TrinityCare Senior Living Announces Funding Agreement for Fifth Senior Living Facility 4Health News:Eucerin Provides BlogHer Attendees With a Glimpse Into Their Skin's Future With Proprietary 'Time Machine' Aging Simulator 2Health News:Clear Choice Health Plans Selects Thomson Reuters to Deliver Healthcare Cost Information to Members - and Exceed State Transparency Requirements 2Health News:Clear Choice Health Plans Selects Thomson Reuters to Deliver Healthcare Cost Information to Members - and Exceed State Transparency Requirements 3Health News:Mt. Lebanon Comes Alive Saturday, August 8th with ULTRAparty 2Health News:The State of Louisiana and Together Rx Access Join Forces to Improve Prescription Access for Uninsured Residents 2Health News:The State of Louisiana and Together Rx Access Join Forces to Improve Prescription Access for Uninsured Residents 3Health News:The State of Louisiana and Together Rx Access Join Forces to Improve Prescription Access for Uninsured Residents 4Health News:Seattle Children's Hospital Deploys CA's Integrated Infrastructure and Performance Management Solution 2Health News:Seattle Children's Hospital Deploys CA's Integrated Infrastructure and Performance Management Solution 3
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
Form: Cream-colored powder Moisture: 10% Ash: 6.5% Gel Strength (1.5%): 550 950 gm/cm 2 Gel pH (1.5%): 6.0 7.5 Gel Point (1.5%): 34 38C Melting Point (1.5%): 84 88C Application: Bacterial ...
... generation of a hypoxic environment for tissue ... surface-type seal where all portions of the ... steel ring clamp for a reliable air-tight ... and bottom provide minimum gas flow resistance ...
... incubators is available, ensuring the customers to ... specific requirements. miniTHERM incubators have a capacity ... space saving. Their size corresponds approximately to ... to stack up to three units on ...
Medicine Products: